Elixiron Immunotherapeutics (Taiwan)
Recent events
Recent events tied to this brand in public sources.
Back to profile2 entries
2021
4B Technologies and Elixiron enter exclusive licensing partnership
4B Technologies (福贝生物) and Elixiron Immunotherapeutics entered an exclusive licensing partnership to jointly advance development, production, and commercialization of CSF1R inhibitor EI-1071 in areas including neurological diseases.
2020
Elixiron receives $1 million research grant
Elixiron Immunotherapeutics announced that it received a $1 million grant through the 2020 Part The Cloud-Gates Partnership program to advance its EI1071 drug toward a Phase I human clinical trial.